Psoriasis drug stelara under safety watch in kids

NCT ID NCT03218488

Ongoing Disease control Sponsor: Janssen-Cilag International NV Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 135 children aged 6 to 17 with moderate to severe plaque psoriasis who are already starting or have recently started treatment with ustekinumab (Stelara). Researchers are monitoring for serious side effects like infections, cancer, and autoimmune issues, as well as effects on growth and puberty. The goal is to understand the long-term safety of this drug in young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ustekinumab (Stelara)

What this could lead to

If successful, this study could confirm that ustekinumab is safe for long-term use in children with psoriasis, helping doctors manage the disease more confidently.

What could go wrong

This is an observational study, not a treatment trial, so it won't test if the drug works better than other options. It only tracks safety, and results may not apply to all children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Locations

Andreas Sygros Hospital

Athens, 16121, Greece
Bispebjerg Hospital

Copenhagen, NV 2400, Denmark
CH Victor Dupouy Argenteuil

Argenteuil, 95107, France
CHRU Besancon Hopital Jean Minjoz

Besançon, 25030, France
CHU Saint Etienne Hopital Nord

Saint-Etienne, 42055, France
CHU de Liège - Domaine Universitaire du Sart Tilman

Liège, 4000, Belgium
FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences

Moscow, 119991, Russia
Gemeinschaftspraxis Dres. Quist

Mainz, 55128, Germany
Gentofte Herlev Hospital

Hellerup, 2800, Denmark
Grand Hôpital de Charleroi

Loverval, 6280, Belgium
Great Ormond Street Hospital

London, WC1N 3JH, United Kingdom
Groupe Hospitalier Pellegrin CHU de Bordeaux

Bordeaux, 33076, France
Hopital Necker Enfants Malades

Paris, 75743, France
ICH Hopital A. Morvan

Brest, 29609, France
Kinderspital Zürich

Zurich, 8032, Switzerland
Le Bateau Blanc

Martigues, 13500, France
Llc Ultramed

Omsk, 644024, Russia
Moscow Research-Practical Center of Dermatovenerology and Cosmetology

Moscow, 119049, Russia
Oslo universitetssykehus HF, Rikshospitalet

Oslo, 0027, Norway
Praxis Dr. med. Beate Schwarz - Germany

Langenau, 89129, Germany
Radboudumc

Nijmegen, 6525 EX, Netherlands
Saint-Petersburg State Pediatric Medical Academy of RosZdrav

Saint Petersburg, 194353, Russia
Salford Royal Hospital

Salford, M6 8HD, United Kingdom
UCL Hopital Saint-Luc

Brussels, 1200, Belgium
UZ Leuven

Leuven, 3000, Belgium
Uniklinik Graz

Graz, 8036, Austria
Universitatsmedizin der Johannes Gutenberg Universitat Mainz

Mainz, 55131, Germany
University Hospital for Skin and Venereal Diseases

Thessaloniki, 54 643, Greece
University Hospital of Wales

Cardiff, CF14 4XW, United Kingdom
Whipps Cross University Hospital

London, E11 1NR, United Kingdom